CD8A and myeloid sarcoma: We also assessed the phenotypes of these CD8+ T cell populations by the expression of memory markers as well as CD20, which is increased on memory CD8+ T cells in MS patients and reduced following anti-CD20 monoclonal antibody (mAb) treatment (35, 36).